BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 15139068)

  • 21. 2,4-Diamino-N10-methylpteroic acid (DAMPA) crystalluria in a patient with osteosarcoma treated with carboxypeptidase-G2 rescue after high-dose methotrexate-induced nephrotoxicity.
    Berga F; Luna P; Martorell C; Rey J; Gomila I; Gimenez S; Costa-Bauza A; Elorza MÁ; Sánchez I; Grases F; Barceló B
    Clin Chim Acta; 2018 Dec; 487():1-5. PubMed ID: 30205081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucarpidase following high-dose methotrexate: update on development.
    Patterson DM; Lee SM
    Expert Opin Biol Ther; 2010 Jan; 10(1):105-11. PubMed ID: 19925307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The need for a better definition of therapeutic indications of carboxypeptidase in delayed elimination of methotrexate].
    Blasco H; Silly S; Tournamille JF; Gyan E; Sénécal D; André V; Colombat P; Le Guellec C
    Therapie; 2008; 63(1):19-28. PubMed ID: 18387272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy.
    Krause AS; Weihrauch MR; Bode U; Fleischhack G; Elter T; Heuer T; Engert A; Diehl V; Josting A
    Leuk Lymphoma; 2002 Nov; 43(11):2139-43. PubMed ID: 12533039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase.
    Vilay AM; Mueller BA; Haines H; Alten JA; Askenazi DJ
    Pharmacotherapy; 2010 Jan; 30(1):111. PubMed ID: 20030480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure.
    Buchen S; Ngampolo D; Melton RG; Hasan C; Zoubek A; Henze G; Bode U; Fleischhack G
    Br J Cancer; 2005 Feb; 92(3):480-7. PubMed ID: 15668713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys.
    Adamson PC; Balis FM; McCully CL; Godwin KS; Poplack DG
    J Clin Oncol; 1992 Aug; 10(8):1359-64. PubMed ID: 1634927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carboxypeptidase G2 rescue in delayed methotrexate elimination in renal failure.
    Mohty M; Peyriere H; Guinet C; Hillaire-Buys D; Blayac JP; Rossi JF
    Leuk Lymphoma; 2000 Apr; 37(3-4):441-3. PubMed ID: 10752997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
    Scott JR; Zhou Y; Cheng C; Ward DA; Swanson HD; Molinelli AR; Stewart CF; Navid F; Jeha S; Relling MV; Crews KR
    Pediatr Blood Cancer; 2015 Sep; 62(9):1518-22. PubMed ID: 25631103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Controlled ultra-high dosage methotrexate therapy in three patients with metastatic osteosarcoma (author's transl)].
    Leber H; Kotz R; Chiari K; Endler T; Gabl F; Krisch K; Salzer-Kuntschik M
    Wien Klin Wochenschr; 1981 Apr; 93(7):236-40. PubMed ID: 7020262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function.
    Hempel L; Misselwitz J; Fleck C; Kentouche K; Leder C; Appenroth D; Rost M; Zintl F
    Med Pediatr Oncol; 2003 Jun; 40(6):348-54. PubMed ID: 12692801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature.
    Delepine N; Delepine G; Bacci G; Rosen G; Desbois JC
    Cancer; 1996 Nov; 78(10):2127-35. PubMed ID: 8918406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
    Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
    Widemann BC; Schwartz S; Jayaprakash N; Christensen R; Pui CH; Chauhan N; Daugherty C; King TR; Rush JE; Howard SC
    Pharmacotherapy; 2014 May; 34(5):427-39. PubMed ID: 24132809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
    Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
    Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Toxicosis of high-dose methotrexate (HD-MTX) for osteosarcoma, cured with treatment by leucovorin (LV) rescue and hemoperfusion--a case report].
    Kobayashi H; Morita T; Hirata Y; Kato T; Okada Y; Sato T
    Gan To Kagaku Ryoho; 2000 Mar; 27(3):475-8. PubMed ID: 10740644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anaphylactoid reaction to high-dose methotrexate and successful desensitization.
    Oulego-Erroz I; Maneiro-Freire M; Bouzón-Alejandro M; Vázquez-Donsión M; Couselo JM
    Pediatr Blood Cancer; 2010 Sep; 55(3):557-9. PubMed ID: 20533520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G2.
    Adamson PC; Balis FM; McCully CL; Godwin KS; Bacher JD; Walsh TJ; Poplack DG
    J Clin Oncol; 1991 Apr; 9(4):670-4. PubMed ID: 2066764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?
    Sterba J; Valík D; Bajciová V; Kadlecová V; Gregorová V; Mendelová D
    Neoplasma; 2005; 52(6):456-63. PubMed ID: 16284689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.